Article

Veeva Systems achieved Q4 CY2025 sales of $836 million, marking a 16% year-on-year increase. The revenue guidance for the next quarter stands at $856.5 million, exceeding analyst expectations. Non-GAAP profit per share was $2.06, 6.5% above consensus estimates.

The company experienced strong demand for modernizing legacy systems, particularly from top pharmaceutical firms, emphasizing the need for scalable solutions. Management noted a focus on AI-driven automation and integration into existing platforms, with expectations for growth in R&D and safety solutions. Veeva aims to leverage contract research organizations to enhance sales opportunities with emerging biotech customers.